Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age

International Journal of Oncology

Volumn 43, Issue 1, 2013, Pages 23-28

  Hoiczyk, Mathias ^a   Grabellus, Florian ^a   Podleska, Lars ^a   Ahrens, Marit ^a   Schwindenhammer, Benjamin ^a   Taeger, Georg ^a   Pöttgen, Christoph ^a   Schuler, Martin ^a   Bauer, Sebastian ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Port complication; Sarcoma; Trabectedin

Indexed keywords

ANTIEMETIC AGENT; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; TRABECTEDIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CHONDROSARCOMA; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; ELDERLY CARE; FATIGUE; FEMALE; FEVER; GROUPS BY AGE; HEMANGIOPERICYTOMA; HUMAN; LEIOMYOSARCOMA; LEUKOPENIA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTPATIENT; OUTPATIENT CARE; PREMEDICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RHABDOMYOSARCOMA; SMALL CELL SARCOMA; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DIOXOLES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEIOMYOSARCOMA; LIPOSARCOMA; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; SARCOMA; TETRAHYDROISOQUINOLINES;

EID: 84879659927     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1928     Document Type: Article

References (19)

1. Sleijfer S, Ouali M, van Glabbeke M, et al: Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer- Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer 46: 72-83, 2010.
2. Reichardt P: High-dose chemotherapy in adult soft tissue sarcoma. Crit Rev Oncol Hematol 41: 157-167, 2002.
3. Antman K, Crowley J, Balcerzak SP, et al: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 11: 1276-1285, 1993. (Pubitemid 23199130)
4. Zewail-Foote M and Hurley LH: Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem 42: 2493-2497, 1999. (Pubitemid 29344290)
5. Minuzzo M, Marchini S, Broggini M, et al: Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci USA 97: 6780-6784, 2000. (Pubitemid 30412791)
6. Takebayashi Y, Pourquier P, Zimonjic DB, et al: Antiproliferative activity of ecteinascidin 743 is dependent upon transcriptioncoupled nucleotide-excision repair. Nat Med 7: 961-966, 2001. (Pubitemid 32756435)
7. Damia G, Silvestri S, Carrassa L, et al: A unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 92: 583-588, 2001. (Pubitemid 32319434)
8. Kanzaki A, Takebayashi Y, Ren XQ, et al: Overcoming multidrug drug resistance in P-glycoprotein/MDR1- overexpressing cell lines by ecteinascidin 743. Mol Cancer Ther 1: 1327-1334, 2002.
9. Delaloge S, Yovine A, Taamma A, Riofrio M, Brain E, Raymond E, Cottu P, Goldwasser F, Jimeno J, Misset JL, Marty M and Cvitkovic E: Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients - preliminary evidence of activity. J Clin Oncol 19: 1248-1255, 2001. (Pubitemid 32202527)
10. Yovine A, Riofrio M, Blay JY, et al: Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 22: 890-899, 2004. (Pubitemid 41103601)
11. Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray-Coquard I, Bonvalot S, Collin F, Jimeno J, Di Paola E, Van Glabbeke M and Nielsen OS: Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 23: 576-584, 2005. (Pubitemid 46224235)
12. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, Quigley MT, Merriam P, Canniff J, Goss G, Matulonis U, Maki RG, Lopez T, Puchalski TA, Sancho MA, Gomez J, Guzman C, Jimeno J and Demetri GD: Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 22: 1480-1490, 2005.
13. Le Cesne A, Judson I, Crowther D, et al: Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 18: 2676-2684, 2002. (Pubitemid 30463549)
14. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gómez J, Park YC and Le Cesne A: Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 27: 4188-4196, 2009.
15. Baruchel S, Pappo A, Krailo M, Baker KS, Wu B, Villaluna D, Lee-Scott M, Adamson PC and Blaney SM: A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group. Eur J Cancer 48: 579-585, 2012.
16. Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, et al: Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 8: 595-602, 2007. (Pubitemid 46995623)
17. Fayette J, Boyle H, Chabaud S, et al: Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution. Anticancer Drugs 21: 113-119, 2010.
18. Theman TA, Hartzell TL, Sinha I, et al: Recognition of a new chemotherapeutic vesicant: trabectedin (Ecteinascidin-743) extravasation with skin and soft tissue damage. J Clin Oncol 27: 198-200, 2009.
19. van Glabbeke M, Verweij J, Judson I, et al: EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 38: 543-549, 2002. (Pubitemid 34185394)